Gilead Sciences

IRS: 943047598
GILD
Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.

Founded
1987 (34 years)
CEO
Daniel O'Day
Investor RelationsSEC
Revenue
22 billion (2020)

Want to see more? Sign up!